CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
PerkinElmer and Verinata Health announced a strategic agreement for expanding access to Verinata’s Verifi test, a comprehensive noninvasive prenatal test (NIPT) for high-risk pregnancies. The Verifi test, performed at Verinata’s CLIA-certified California laboratory, uses a single maternal blood draw at as early as 10 weeks of pregnancy to detect multiple fetal chromosomal aneuploidies. Under terms of the collaboration, PerkinElmer will serve as an exclusive Verinata partner in joint sales and marketing of the Verifi test.
Highly accurate biochemical screening results can be received as early as 11 weeks gestation, through PerkinElmer’s NTD Labs offering for Down syndrome and other chromosomal abnormalities. The Verifi prenatal test can be considered for women who have received high-risk first-trimester screening results at NTD Labs early in the first trimester of pregnancy.
The test analyzes genetic material naturally found in a pregnant woman’s blood to detect common fetal chromosome abnormalities. When directed by a physician, the test can be offered to pregnant women of at least 10 weeks gestation at high risk of carrying a fetus with a genetic abnormality.
PerkinElmer, 408-565-0850
Verinata Health, 650-503-5200